Concordance of resistance profiles in households of patients with multidrug-resistant tuberculosis

Clinical Infectious Diseases

Volumn 58, Issue 3, 2014, Pages 392-395

  Parr, Jonathan B ^a,b,c   Mitnick, Carole D ^a,b,c   Atwood, Sidney S ^a   Chalco, Katiuska ^c   Bayona, Jaime ^c   Becerra, Mercedes C ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PARTNERS IN HEALTH   (United States)

Author keywords

contact; discordant; DST; empirical; presumptive

Indexed keywords

AMIKACIN; CAPREOMYCIN; ETHAMBUTOL; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; HOUSEHOLD; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RISK ASSESSMENT;

CONTACT; DISCORDANT; DST; EMPIRICAL; PRESUMPTIVE;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FAMILY CHARACTERISTICS; FAMILY HEALTH; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84892754679     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit709     Document Type: Article

References (13)

1. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9:153-61.
2. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49(RR-6):1-51
3. Tuberculosis Coalition for Technical Assistance. International standards for tuberculosis care. The Hague: Tuberculosis Coalition for Technical Assistance, 2006.
4. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update. Geneva, Switzerland: WHO, 2008.
5. Bayona J, Chavez-Pachas AM, Palacios E, Llaro K, Sapag R, Becerra MC. Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2003; 7(12 suppl 3):S501-9.
6. Becerra MC, Appleton SC, Franke MF, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2011; 377:147-52.
7. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-74.
8. Mitnick CD, Franke MF, Rich ML, et al. Aggressive regimens for multi-drug-resistant tuberculosis decrease all-cause mortality. PLoS One 2013; 8:e58664.
9. Franke MF, Appleton SC, Mitnick CD, et al. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis 2013; 56:770-6.
10. Seddon JA, Godfrey-Faussett P, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Management of children exposed to multidrug-resistant Mycobac-terium tuberculosis. Lancet Infect Dis 2012; 12:469-79.
11. Seddon JA, Jordaan AM, Victor TC, Schaaf HS. Discordant drug susceptibility for Mycobacterium tuberculosis within families. Pediatr Infect Dis J 2012; 31:783-5.
12. Furin JJ, Becerra MC, Shin SS, Kim JY, Bayona J, Farmer PE. Effect of administering short-course, standardized regimens in individuals infected with drug-resistant Mycobacterium tuberculosis strains. Eur J Clin Microbiol Infect Dis 2000; 19:132-6.
13. Cohen T, Murray M, Abubakar I, et al. Multiple introductions of multi-drug-resistant tuberculosis into households, Lima, Peru. Emerg Infect Dis 2011; 17:969-75. Diseases